<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699202</url>
  </required_header>
  <id_info>
    <org_study_id>AK0529-2002</org_study_id>
    <nct_id>NCT03699202</nct_id>
  </id_info>
  <brief_title>Anti-RSV Study in Chinese Patients (ASCENT)</brief_title>
  <acronym>ASCENT</acronym>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Orally Administered AK0529 in Adults With Respiratory Syncytial Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ark Biosciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ark Biosciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study to
      evaluate the efficacy, safety and tolerability of orally administered AK0529 in Chinese
      adults with RSV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study in Chinese
      adult outpatients with RSV infection. Approximately 160 eligible patients who have been
      recently diagnosed with RSV infection are planned to be enrolled into the study. Symptom
      scores of patients before and after treatment will be evaluated. Meanwhile, nasopharyngeal
      samples and blood samples will be collected for virological and pharmacokinetics evaluations.
      The evaluation of the safety and tolerability will include AE/SAE, vital signs, physical
      examination, laboratory examination and 12-lead ECGs. The total study duration for each
      patient will be 20 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of symptom score</measure>
    <time_frame>From Day 0 to Day 5</time_frame>
    <description>To evaluate the change of patient-reported symptom score in AK0529 arms compared with the change in placebo arm after treatment. The scale is Wang bronchiolitis score and the total score is reported with a range from 0 to 12. A decreasing value of total score represents clinical improvement. Subscales are not applicable in this symptom score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events during the study</measure>
    <time_frame>From Day -3 to Day 14</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject withdrawals due to treatment-emergent adverse events</measure>
    <time_frame>From Day -3 to Day 14</time_frame>
    <description>A treatment-emergent adverse event (TEAE) is an AE that first appears during treatment, which was absent before or which worsens relative to the pre-treatment state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve change of viral load</measure>
    <time_frame>From Day 0 to Day 5</time_frame>
    <description>The antiviral effects in adults with RSV infection are to be determined by measuring the RSV viral load area under the curve from baseline to last administration of study medication .</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>100mg AK0529 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg AK0529 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300mg AK0529 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomised into this arm will be orally administered with placebo q.d. for five days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK0529</intervention_name>
    <description>AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.</description>
    <arm_group_label>100mg AK0529 Arm</arm_group_label>
    <arm_group_label>200mg AK0529 Arm</arm_group_label>
    <arm_group_label>300mg AK0529 Arm</arm_group_label>
    <other_name>Ziresovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 75 years, inclusive.

          -  Confirmed with RSV infection by rapid diagnostic testing.

          -  New onset with documentation of the following symptoms within 72 hours prior to the
             start of screening: Respiratory symptoms: runny nose, stuffy nose, sneezing, sore
             throat, earache, cough, shortness of breath; Systemic symptoms: headache, fatigue /
             lethargy, fever, and muscle and / or joint ache. The patient must have four symptoms
             of above, and at least one of these must be respiratory symptom in nature.

          -  Able and willing to provide written informed consent and to comply with the study
             protocol.

        Exclusion Criteria:

          -  The patient has taken, is taking or needs to take any antiviral medication (e.g.
             ribavirin, Chinese medicine or herbs with effects of treating respiratory tract
             infection) within the 72 hours prior to screening.

          -  Awareness of concomitant infections of respiratory viruses (eg, influenza A, B),
             bacterial or fungal infections, including systemic bacterial or fungal infections
             within 7 days prior to screening or during the screening period.

          -  Patient frailty was evaluated as &quot;Vulnerable&quot; or worse according to the Clinical
             Frailty Scale with a score ≥ 4 at screening.

          -  Awareness of having positive results on HBsAg or HCV antibody or HIV (HIV 1 or HIV 2).

          -  Patient with active tuberculosis or is taking antituberculosis treatment.

          -  Patient with severe gastrointestinal disease which could impact drug absorption, eg,
             vomiting, malabsorption syndrome, or short bowel syndrome caused by necrotizing
             enterocolitis.

          -  Patient with any congenital heart disease, acute or chronic heart failure, ischemic
             heart disease, or congenital long QT syndrome, or any clinical manifestation resulting
             in QT interval prolongation.

          -  Patient with malignant tumor.

          -  Patient has received or is waiting for bone marrow, stem cell or solid organ
             transplantation.

          -  Patient with any immune-related disease to be treated within 12 months prior to
             screening.

          -  Patient with clinical laboratoy test values of ≥ 2x the upper limit of normal (ULN)
             for alanine aminotransferase or aspartate aminotransferase, or &gt;1x ULN for total
             bilirubin, or &gt;1.5xULN for serum creatinine.

          -  Patient with electrolyte disorders, eg, hypokalemia, hypocalcemia, or hypomagnesemia.

          -  Patient with history of drug or alcohol abuse within 12 months prior to screening
             (&quot;alcohol abuse&quot; definition is &gt;14 units per week: 1 unit = 10mL Alcohol, or 250mL of
             4% beer, or 25 mL of 40% spirit, or 75 mL of 13% wine).

          -  Patient has allergy or hypersensitivity to study medication or its compositions.

          -  Female patient with positive pregnancy test result or is lactating.

          -  Patient with fertility refusing to use medically effective contraceptives during the
             study or within three months of the end of study.

          -  Patient participated in an investigational drug or device study within 60 days prior
             to screening.

          -  Patient who in the opinion of the investigator, is deemed as ineligible for the study,
             including patients who are with active psychiatric disease, or are taking psychiatric
             medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ark Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>info@arkbiosciences.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Ditan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quanzhou First Hospital</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <zip>362000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huizhou Municipal Central Hospital</name>
      <address>
        <city>Huizhou</city>
        <state>Guangdong</state>
        <zip>516001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Hainan Medical University</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>571199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanya Central Hospital</name>
      <address>
        <city>Sanya</city>
        <state>Hainan</state>
        <zip>572000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Taizhou People's Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Jiangsu</state>
        <zip>225300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qingdao Municipal Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Deyang City</name>
      <address>
        <city>Deyang</city>
        <state>Sichuan</state>
        <zip>618000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suining Central Hopital</name>
      <address>
        <city>Suining</city>
        <state>Sichuan</state>
        <zip>629000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Pinggu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>101200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantong First People's Hospital</name>
      <address>
        <city>Nantong</city>
        <zip>226001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Hospital of Minhang District, Shanghai</name>
      <address>
        <city>Shanghai</city>
        <zip>201199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <zip>518001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangtan Central Hospital</name>
      <address>
        <city>Xiangtan</city>
        <zip>411100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinxiang First People's Hospital</name>
      <address>
        <city>Xinxiang</city>
        <zip>453000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Zunyi Medical University</name>
      <address>
        <city>Zunyi</city>
        <zip>563000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ark Clinical Trial</last_name>
      <phone>+86-21-58350139</phone>
      <email>info@arkbiosciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RSV,AK0529,Chinese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

